- Stocks diverge, oil retreats as China disappoints markets
- Trio wins economics Nobel for work on wealth inequality
- Ex-Stasi officer jailed over 1974 Berlin border killing
- Shanghai stocks gain after stimulus briefing as markets rally
- Shanghai stocks gain after stimulus briefing as Asian markets rally
- Nearly 90, but opera legend Kabaivanska is still calling tune
- With inflation down, ECB eyes faster tempo of rate cuts
- Is life possible on a Jupiter moon? NASA goes to investigate
- Ex-Stasi officer faces verdict over 1974 Berlin border killing
- Role of government, poverty research tipped for economics Nobel
- In milestone, SpaceX 'catches' megarocket booster after test flight
- In a first, SpaceX 'catches' megarocket booster after test flight
- Bangladeshi Hindus shrug off attack worries to celebrate festival
- Ubisoft fears assassin's hit over falling sales
- Vietnam, China hold talks on calming South China Sea tensions
- SpaceX will try to 'catch' giant Starship rocket shortly before landing
- Japan's former empress Michiko discharged after surgery: reports
- Japan's former empress Michiko discharged after surgey: reports
- 'Little Gregory' murder haunts France 40 years on
- Tariffs, tax cuts, energy: What is in Trump's economic plan?
- Amazon wants to be everything to everyone
- Jewish school in Canada hit by gunfire for second time
- With medical report Harris seeks to play health card against Trump
- China-EU EV tariff talks in Brussels end with 'major differences': Beijing
- Buried Nazi past haunts Athens on liberation anniversary
- Harris to release medical report confirming fitness for presidency: campaign
- Nobel prize a timely reminder, Hiroshima locals say
- China offers $325 bn in fiscal stimulus for ailing economy
- Small Quebec company dominates one part of NHL hockey: jerseys
- Boeing to cut 10% of workforce as it sees big Q3 loss
- Want to film in Paris? No sexism allowed
- US, European markets rise as investors weigh rates, earnings
- In Colombia, children trade plastic waste for school supplies
- JPMorgan Chase profits top estimates, bank sees 'resilient' US economy
- Little progress at key meet ahead of COP29 climate summit
- 'Party atmosphere': Skygazers treated to another aurora show
- Kyrgyzstan opens rare probe into glacier destruction
- European Mediterranean states discuss Middle East, migration
- Thunberg leads pro-Palestinian, climate protest in Milan
- Stock markets diverge before China weekend briefing
- EU questions shopping app Temu over illegal products risk
- Han Kang's books sell out in South Korea after Nobel win
- Shanghai markets sink ahead of briefing on mixed day for Asia
- Investors, analysts eye bigger China stimulus at Saturday briefing
- Musk unveils robotaxi, pledges it 'before 2027'
- At least 11 dead in Florida but Hurricane Milton not as bad as feared
- Asian markets mixed after Wall St drop, Shanghai dips before briefing
- Automaker Stellantis says CEO will retire in 2026
- Musk's promised robotaxi unveil delayed
- On US coast, wind power foes embrace 'Save the Whales' argument
EU approves first vaccine against common respiratory virus
The European Commission has followed the United States in approving the world's first vaccine for the Respiratory Syncytial Virus, to be used by adults aged 60 and over, its maker GlaxoSmithKline said Wednesday.
The United States approved the drug, named Arexvy, last month, while the vaccine is the culmination of a decades-long hunt to protect vulnerable people from the common illness.
RSV normally causes mild, cold-like symptoms, but can be serious for infants and the elderly, as well as those with weak immune systems and underlying conditions.
In severe cases it can cause pneumonia and bronchiolitis, an inflammation of the small airways deep inside the lungs.
Analysts predict the market could be worth more than $10 billion in the next decade, with similar shots from other makers including Pfizer and Moderna expected to follow soon.
"This authorisation for Arexvy means eligible adults can be vaccinated against RSV disease for the first time," GSK's chief scientific officer Tony Wood said in a statement.
GSK said RSV is "a common, contagious respiratory virus that leads to... approximately 20,000 in-hospital deaths each year in adults aged 60 years and over in Europe".
The company's shares traded flat in early London deals following the expected approval announcement.
Rates of RSV and flu fell during Covid-19 lockdowns, but surged when restrictions were lifted, with young children hit hard.
- 83% effective -
Stella Kyriakides, EU commissioner for health and food safety, said she hoped the vaccine would prevent problems encountered last winter.
"The Covid pandemic clearly showed the need for decisive action to better prepare the EU for emerging health threats," she said in separate statement.
"I now encourage member states to quickly build on this authorisation and define national vaccination strategies so that those most at risk can access them in the coming months ahead of the next autumn season."
The European Union's drug watchdog in April recommended Arexvy's approval following a trial on 25,000 participants in 17 countries.
The results showed that the vaccine was 83 percent effective at protecting against RSV-related diseases in people aged 60 years or over, with generally mild side effects, according to the European Medicines Agency.
The vaccine uses an engineered protein and an adjuvant substance to promote antibodies and T cells that help fight off RSV infection.
Moderna hopes its RSV vaccine will be approved and be made available by the end of the year.
The EU in 2022 approved a preventative treatment against RSV, developed by British pharmaceutical firm AstraZeneca and France's Sanofi, which works similarly to a vaccine.
burs-bcp/lth
X.Cheung--CPN